Saam A Mojtahed1, Nicole R Boyer2, Saieesh A Rao1, Thomas F Gajewski3, Jennifer Tseng4, Kiran K Turaga5. 1. Pritzker School of Medicine, Division of Biological Sciences, University of Chicago, Chicago, IL, USA. 2. Center for Health and the Social Sciences, University of Chicago, Chicago, IL, USA. 3. Department of Pathology, Division of Biological Sciences, University of Chicago, Chicago, IL, USA. 4. Department of Surgery, Division of Biological Sciences, The University of Chicago, Chicago, IL, USA. 5. Department of Surgery, Division of Biological Sciences, The University of Chicago, Chicago, IL, USA. kturaga@surgery.bsd.uchicago.edu.
Abstract
BACKGROUND: Adjuvant therapy for stage III melanoma improves several measures of patient survival. However, decisions regarding inclusion of adjuvant therapies in the formularies of public payers necessarily consider the cost-effectiveness of those treatments. The objective of this study is to evaluate the cost-effectiveness of four recently approved adjuvant therapies for BRAF-mutant stage III melanoma in the Medicare patient population. METHODS: In this cost-effectiveness analysis, a Markov microsimulation model was used to simulate the healthcare trajectory of patients randomized to receive either first-line targeted therapy (dabrafenib-trametinib) or immunotherapy (ipilimumab, nivolumab, or pembrolizumab). The base case was a 65-year-old Medicare patient with BRAF V600E-mutant resected stage III melanoma. Possible health states included recurrence-free survival, adverse events, local recurrence, distant metastases, and death. Transition probabilities were determined from published clinical trials. Costs were estimated from reimbursement rates reported by CMS and the Red Book drug price database. Primary outcomes were costs (US$), life years, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs). Model robustness was evaluated using one-way and probabilistic sensitivity analyses. RESULTS: Dabrafenib-trametinib provided 1.83 QALYs over no treatment and 0.23 QALYs over the most effective immunotherapy, pembrolizumab. Dabrafenib-trametinib was associated with an ICER of $95,758/QALY over no treatment and $285,863/QALY over pembrolizumab. Pembrolizumab yielded an ICER of $68,396/QALY over no treatment and dominated other immunotherapies. CONCLUSIONS:Pembrolizumab is cost-effective at a conventional willingness-to-pay (WTP) threshold, but dabrafenib-trametinib is not. Though dabrafenib-trametinib offers incremental QALYs, optimization of drug pricing is necessary to ensure dabrafenib-trametinib is accessible at an acceptable WTP threshold.
RCT Entities:
BACKGROUND: Adjuvant therapy for stage III melanoma improves several measures of patient survival. However, decisions regarding inclusion of adjuvant therapies in the formularies of public payers necessarily consider the cost-effectiveness of those treatments. The objective of this study is to evaluate the cost-effectiveness of four recently approved adjuvant therapies for BRAF-mutant stage III melanoma in the Medicare patient population. METHODS: In this cost-effectiveness analysis, a Markov microsimulation model was used to simulate the healthcare trajectory of patients randomized to receive either first-line targeted therapy (dabrafenib-trametinib) or immunotherapy (ipilimumab, nivolumab, or pembrolizumab). The base case was a 65-year-old Medicare patient with BRAFV600E-mutant resected stage III melanoma. Possible health states included recurrence-free survival, adverse events, local recurrence, distant metastases, and death. Transition probabilities were determined from published clinical trials. Costs were estimated from reimbursement rates reported by CMS and the Red Book drug price database. Primary outcomes were costs (US$), life years, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs). Model robustness was evaluated using one-way and probabilistic sensitivity analyses. RESULTS:Dabrafenib-trametinib provided 1.83 QALYs over no treatment and 0.23 QALYs over the most effective immunotherapy, pembrolizumab. Dabrafenib-trametinib was associated with an ICER of $95,758/QALY over no treatment and $285,863/QALY over pembrolizumab. Pembrolizumab yielded an ICER of $68,396/QALY over no treatment and dominated other immunotherapies. CONCLUSIONS:Pembrolizumab is cost-effective at a conventional willingness-to-pay (WTP) threshold, but dabrafenib-trametinib is not. Though dabrafenib-trametinib offers incremental QALYs, optimization of drug pricing is necessary to ensure dabrafenib-trametinib is accessible at an acceptable WTP threshold.
Authors: James Larkin; Vanna Chiarion-Sileni; Rene Gonzalez; Jean-Jacques Grob; Piotr Rutkowski; Christopher D Lao; C Lance Cowey; Dirk Schadendorf; John Wagstaff; Reinhard Dummer; Pier F Ferrucci; Michael Smylie; David Hogg; Andrew Hill; Ivan Márquez-Rodas; John Haanen; Massimo Guidoboni; Michele Maio; Patrick Schöffski; Matteo S Carlino; Céleste Lebbé; Grant McArthur; Paolo A Ascierto; Gregory A Daniels; Georgina V Long; Lars Bastholt; Jasmine I Rizzo; Agnes Balogh; Andriy Moshyk; F Stephen Hodi; Jedd D Wolchok Journal: N Engl J Med Date: 2019-09-28 Impact factor: 91.245
Authors: Reinhard Dummer; Jan C Brase; James Garrett; Catarina D Campbell; Eduard Gasal; Matthew Squires; Daniel Gusenleitner; Mario Santinami; Victoria Atkinson; Mario Mandalà; Vanna Chiarion-Sileni; Keith Flaherty; James Larkin; Caroline Robert; Richard Kefford; John M Kirkwood; Axel Hauschild; Dirk Schadendorf; Georgina V Long Journal: Lancet Oncol Date: 2020-01-30 Impact factor: 41.316
Authors: Alexander M M Eggermont; Vanna Chiarion-Sileni; Jean-Jacques Grob; Reinhard Dummer; Jedd D Wolchok; Henrik Schmidt; Omid Hamid; Caroline Robert; Paolo A Ascierto; Jon M Richards; Céleste Lebbé; Virginia Ferraresi; Michael Smylie; Jeffrey S Weber; Michele Maio; Lars Bastholt; Laurent Mortier; Luc Thomas; Saad Tahir; Axel Hauschild; Jessica C Hassel; F Stephen Hodi; Corina Taitt; Veerle de Pril; Gaetan de Schaetzen; Stefan Suciu; Alessandro Testori Journal: N Engl J Med Date: 2016-10-07 Impact factor: 91.245
Authors: Ingmar Blumcke; Roberto Spreafico; Gerrit Haaker; Roland Coras; Katja Kobow; Christian G Bien; Margarete Pfäfflin; Christian Elger; Guido Widman; Johannes Schramm; Albert Becker; Kees P Braun; Frans Leijten; Johannes C Baayen; Eleonora Aronica; Francine Chassoux; Hajo Hamer; Hermann Stefan; Karl Rössler; Maria Thom; Matthew C Walker; Sanjay M Sisodiya; John S Duncan; Andrew W McEvoy; Tom Pieper; Hans Holthausen; Manfred Kudernatsch; H Joachim Meencke; Philippe Kahane; Andreas Schulze-Bonhage; Josef Zentner; Dieter H Heiland; Horst Urbach; Bernhard J Steinhoff; Thomas Bast; Laura Tassi; Giorgio Lo Russo; Cigdem Özkara; Buge Oz; Pavel Krsek; Silke Vogelgesang; Uwe Runge; Holger Lerche; Yvonne Weber; Mrinalini Honavar; José Pimentel; Alexis Arzimanoglou; Adriana Ulate-Campos; Soheyl Noachtar; Elisabeth Hartl; Olaf Schijns; Renzo Guerrini; Carmen Barba; Thomas S Jacques; J Helen Cross; Martha Feucht; Angelika Mühlebner; Thomas Grunwald; Eugen Trinka; Peter A Winkler; Antonio Gil-Nagel; Rafael Toledano Delgado; Thomas Mayer; Martin Lutz; Basilios Zountsas; Kyriakos Garganis; Felix Rosenow; Anke Hermsen; Tim J von Oertzen; Thomas L Diepgen; Giuliano Avanzini Journal: N Engl J Med Date: 2017-10-26 Impact factor: 91.245
Authors: Paolo A Ascierto; John M Kirkwood; Jean-Jacques Grob; Ester Simeone; Antonio M Grimaldi; Michele Maio; Giuseppe Palmieri; Alessandro Testori; Francesco M Marincola; Nicola Mozzillo Journal: J Transl Med Date: 2012-07-09 Impact factor: 5.531
Authors: Zachary J Ward; Michael W Long; Stephen C Resch; Catherine M Giles; Angie L Cradock; Steven L Gortmaker Journal: N Engl J Med Date: 2017-11-30 Impact factor: 176.079